Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31 - Earnings Summary

Kalvista Pharmaceuticals

12/03/2025 12:45

Kalvista Pharmaceuticals Inc KALV.OQ reported a quarterly adjusted loss of 78 cents​​ per share for the quarter ended January 31, higher than the same quarter last year, when the company reported EPS of -84 cents.  The mean expectation of ten analysts for the quarter was for a loss of 87 cents per share. Wall Street expected results to range from -98 cents to -80 cents per share.

Reported revenue was zero​; analysts expected zero.

Kalvista Pharmaceuticals Inc's reported EPS for the quarter was a loss of 92 cents​.

The company reported a quarterly loss of $44.26 million.

Kalvista Pharmaceuticals Inc shares had risen by 46.8% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1.8% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Kalvista Pharmaceuticals Inc is $28.00

This summary was machine generated from LSEG data March 12 at 12:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jan. 31 2025
-0.87
-0.78
Beat
Oct. 31 2024
-0.91
-0.91
Met
Jul. 31 2024
-0.91
-0.87
Beat
Apr. 30 2024
-0.73
-1.02
Missed